RetaMaps

Cosmetica Laser & Skin: Laser Hair Removal, Botox, Lip Fillers, Semaglutide, Microneedling, HydraFacial, BioRepeel

Cosmetica Laser & Skin: Laser Hair Removal, Botox, Lip Fillers, Semaglutide, Microneedling, HydraFacial, BioRepeel · 1133 Gray Avenue · Yuba City, CA 95991

5.0· 228 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • GLP-1 medications named on site
  • Medically supervised weight loss

About this practice

Cosmetica Laser & Skin is a medical spa in Yuba City, California. Its website lists laser hair removal, neuromodulators such as Botox and Dysport, fillers, microneedling, a CO2 laser peel, Hydrafacial and semaglutide for weight loss. Because it is a med spa rather than a dedicated weight-loss clinic, anyone considering semaglutide here should ask who prescribes it and how visits are supervised. On Google it holds a 5.0-star rating across 228 reviews since 2024, with 98 posted in the past year, and reviewers most often mention the staff, followed by the providers' knowledge and results.

Services & access

Advertises semaglutide todayYes
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 5.0
Google rating · 228 reviews
98
reviews in the past year (avg ★ 5.0)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-29. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★5.0 across 228 Google reviews. Of the 100 reviews we analyzed, 100 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).

What patients like

  • Friendly, helpful staff41 reviews
  • Knowledgeable, professional providers21 reviews
  • Weight-loss results19 reviews
  • Clean, comfortable office10 reviews

Common complaints

No negative reviews among those we analyzed.

5★
100
4★
0
3★
0
2★
0
1★
0

Most recent Google reviews

steven S.★★★★★2026-09-29

Amazing Place and welcoming atmosphere Liz and her team are very professional and make every appointment feel great

S. D.★★★★★2026-09-29

love it here. Got microneedling done and the whole experience was seamless and results are great!

Chantal C.★★★★★2026-09-19

Great bilingual staff!

Carmen C.★★★★★2026-09-19

Quick & great staff¡

brisa g.★★★★★2026-09-01

Amazing work im obsessed 😍

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Yuba City

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs